Expression of wilms tumor gene(WT1) in leukemia patients and its clinical significance
Shi Lin-x
Abstract
Shi Lin-x
Abstract
Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication. Methods Nest RT-PCR technique was applied to examine WT1 gene expression in 50 patients with leukemia. Results The WT1 mRNA positive rates in acute myeloid leukemias and lymphoblastic leukemias were 77.3% (17/22) and 54.5%(6/11) . In chronic myeloid leukemia, WT1 mRNA was undetectable at chronic phase ; but was revealed in 5 of 9 patients at blast crisis (55.6 %). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1 (31.3 % vs 69.2 %, P 0.05). Conclusion The WT1 was highly expressed in the majority of the patients with leukemia and thus was involved in human leukemogenesis. It indicated WT1 could be a new prognostic factor and a panleukemia marker for the detection of MRD.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To evaluate the expression of WT1 gene in leukemia patients and its clinical implication. Methods Nest RT-PCR technique was applied to examine WT1 gene expression in 50 patients with leukemia. Results The WT1 mRNA positive rates in acute myeloid leukemias and lymphoblastic leukemias were 77.3% (17/22) and 54.5%(6/11) . In chronic myeloid leukemia, WT1 mRNA was undetectable at chronic phase ; but was revealed in 5 of 9 patients at blast crisis (55.6 %). The rate of remission in the patients positive for WT1 was lower than in those negative for WT1 (31.3 % vs 69.2 %, P 0.05). Conclusion The WT1 was highly expressed in the majority of the patients with leukemia and thus was involved in human leukemogenesis. It indicated WT1 could be a new prognostic factor and a panleukemia marker for the detection of MRD.
Key concepts: Myeloid leukemia, Wilms' tumor, Leukemia, Cancer research, Clinical significance, Gene, Medicine, Internal medicine